Trial Profile

Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Cytarabine
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Apr 2020 Status changed from active, no longer recruiting to completed.
08 Jan 2020 Planned End Date changed from 15 Dec 2019 to 15 Mar 2020.
29 Oct 2019 Planned End Date changed from 15 Oct 2019 to 15 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com